Synucure Therapeutics
Canadian biotechnology company (founded 2021) focused on research and development of disease‑modifying therapies and diagnostic tools for neurodegenerative disorders, with primary programs on repurposing and reformulation of a brain‑penetrant small molecule for Parkinson’s disease and the development/validation of patented blood‑based biomarkers for faster, more precise diagnosis and stratification.
Industries
Nr. of Employees
small (1-50)
Products
Novel formulation of a brain‑penetrant small molecule (clinical candidate)
Development of a novel formulation derived from an existing brain‑penetrant small molecule intended as a disease‑modifying therapy for Parkinson's disease; program advanced from preclinical development toward clinical initiation.
Novel formulation of a brain‑penetrant small molecule (clinical candidate)
Development of a novel formulation derived from an existing brain‑penetrant small molecule intended as a disease‑modifying therapy for Parkinson's disease; program advanced from preclinical development toward clinical initiation.
Services
Discovery, analytical validation and IP management of blood‑based biomarker assays to support diagnosis and stratification of Parkinson's disease.
Preclinical evaluation of small‑molecule candidates including pharmacology, toxicology, formulation planning and translational efficacy studies in cell and animal models.
Design and operational management of clinical programs, including trial design, CRO/CMO coordination and outcome evaluation.
Discovery, analytical validation and IP management of blood‑based biomarker assays to support diagnosis and stratification of Parkinson's disease.
Preclinical evaluation of small‑molecule candidates including pharmacology, toxicology, formulation planning and translational efficacy studies in cell and animal models.
Design and operational management of clinical programs, including trial design, CRO/CMO coordination and outcome evaluation.
Expertise Areas
- Neurodegenerative disease drug development
- Biomarker discovery and diagnostic assay development
- Translational neuroscience and preclinical pharmacology
- Clinical trial design and management
Key Technologies
- Blood‑based biomarker assays
- Proteomic and genomic analyses
- Animal and cellular models of neurodegeneration
- Neuroimaging (MRI, PET) and image analysis
News & Updates
Execution of an exclusive license with an academic institution for use and development of proprietary and patented blood biomarkers for Parkinson’s disease.
Biomarkers program for Parkinson’s disease completed and development of the novel small‑molecule formulation initiated.
Completion of a drug development plan with external experts for a novel formulation intended to meet clinical needs in Parkinson’s disease.
Announcement of a $2.8 million investment to support development of a treatment for Parkinson's disease.
First meeting of the company's Scientific Advisory Board to support scientific and clinical development directions.
Execution of an exclusive license with an academic institution for use and development of proprietary and patented blood biomarkers for Parkinson’s disease.
Biomarkers program for Parkinson’s disease completed and development of the novel small‑molecule formulation initiated.
Completion of a drug development plan with external experts for a novel formulation intended to meet clinical needs in Parkinson’s disease.
Announcement of a $2.8 million investment to support development of a treatment for Parkinson's disease.
First meeting of the company's Scientific Advisory Board to support scientific and clinical development directions.